1. Acucela

    0 Comments Leave a Comment

    1-3 of 3
    1. Mentioned In 3 Articles

    2. Automated thresholding algorithms outperform manual thresholding in macular optical coherence tomography angiography image analysis

      Automated thresholding algorithms outperform manual thresholding in macular optical coherence tomography angiography image analysis
      ... Bayer, Bioeg, Boehringer-Ingelheim, Genentech/Roche, Heidelberg Engineering, Novartis, and Thea, grants from Acucela, Allergan, Bayer, Bioeq, Genentech/Roche, Merz, NightstarX, and Novartis, honoraria from Allergan, Bay...
      Read Full Article
    3. Acucela Meets with NASA and TRISH for Phase 1 Update for SS-OCT Project

      Acucela Meets with NASA and TRISH for Phase 1 Update for SS-OCT Project
      ...oldings.co.jp/en/1/index.html Acucela, the Acucela logo and Kubota are registered trademarks or trademarks of Acucela Inc. or Kubota Pharmaceutical Holdings in various jurisdictions. Acucela Inc. (“Acucela”), a clinical-...
      Read Full Article
    4. 1-3 of 3
  1. Categories

    1. Applications:

      Art, Cardiology, Dentistry, Dermatology, Developmental Biology, Gastroenterology, Gynecology, Microscopy, NDE/NDT, Neurology, Oncology, Ophthalmology, Other Non-Medical, Otolaryngology, Pulmonology, Urology
    2. Business News:

      Acquisition, Clinical Trials, Funding, Other Business News, Partnership, Patents
    3. Technology:

      Broadband Sources, Probes, Tunable Sources
    4. Miscellaneous:

      Jobs & Studentships, Student Theses, Textbooks
  2. About Acucela

    Acucela

    Acucela Inc. is a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596) committed to translating innovation into a diverse portfolio of drugs and devices to preserve and restore vision for millions of people worldwide. Acucela’s development pipeline include drug candidates for the treatment of diabetic retinopathy, Stargardt disease, and optogenetics-based gene therapy for the treatment of retinitis pigmentosa. The company is also developing a handheld OCT device for the monitoring of neovascular retinal diseases, to be used directly by patients. https://www.acucela.com ; https://www.kubotaholdings.co.jp/en/